As of Thursday, January 08, Monte Rosa Therapeutics, Inc.’s GLUE share price has surged by 8.03%, which has investors ...

Monte Rosa’s MRT-8102 Phase 1 shows deep NEK7 degradation and strong hsCRP drops; plus $200M raise extends runway. Learn more ...

Monte Rosa Therapeutics (GLUE) drew fresh attention after reporting strong interim Phase 1 results for MRT-8102, its NEK7-directed molecular glue degrader. The data showed rapid, sustained reductions ...

Jefferies, TD Cowen and Piper Sandler are acting as joint book-running managers for the offering. Wedbush PacGrow and LifeSci Capital are acting as passive bookrunners for the offering.

Monte Rosa Therapeutics (GLUE) announced a public offering of 11,125,000 shares of its common stock at $24.00 each. It will ...

Clinical-stage biotechnology company Monte Rosa Therapeutics Inc. (NASDAQ: GLUE) on Wednesday revealed interim data from an ...

Shares in Monte Rosa Therapeutics (NASDAQ:GLUE) climbed around 13% after the company released encouraging interim results ...

Jefferies, TD Cowen and Piper Sandler are acting as joint book-running managers for the offering. Wedbush PacGrow and LifeSci Capital are acting as passive bookrunners for this offering.

Shares of Monte Rosa Therapeutics climbed after the company said its treatment for inflammatory diseases showed rapid and durable reductions in systemic inflation during an early-stage trial. The ...

Novartis has ventured back to Monte Rosa Therapeutics tasked with finding more immune-mediated disease drug candidates, signing a licensing deal worth up to $5.7bn. The agreement will see Novartis pay ...

Monte Rosa Therapeutics is at it again, banking $95 million just six months after reeling in a $96 million series B. The funds will propel the company’s lead protein-degrading program into the clinic ...

Shares of Monte Rosa Therapeutics climbed after the company said it will host a call Wednesday to review results from an early-stage trial of its treatment of inflammatory diseases. The stock rose 8.7 ...